A new Northwestern University study using patient nervous tissue and lab-grown human neurons has uncovered how a key disease ...
Shanghai Zhimeng Biopharma Inc. ( "Zhimeng") announced that its self-developed new-generation potassium channel opener CB03-154 for the treatment of amyotrophic lateral sclerosis (ALS) has officially ...
A new Northwestern University study using patient nervous tissue and lab-grown human neurons has uncovered how a key disease protein, TDP-43, drives overactive nerve cells in the neurodegenerative ...
In the MIROCALS trial, Gilbert Bensimon and colleagues1 showed that low-dose interleukin-2 (IL-2) added to riluzole did not significantly reduce mortality in an unadjusted analysis of patients with ...
We thank Yutaka Shimazu for his insightful comments. We agree that our positive findings1–4 highlight the urgent need for further work on biomarkers of neuronal damage and immune mechanisms in ...
Testing showed that Gonzalez’ ALS was caused by a mutation in the SOD1 gene (Super Oxide Dismutase 1), which meant she was ...
Despite modern imaging and genetic testing, diagnosing amyotrophic lateral sclerosis (ALS) remains challenging, particularly ...
The FDA has granted orphan drug status to the experimental T-cell, or Treg, therapy CK0803, being developed by Cellenkos to treat ALS.
La Jolla scientists at the La Jolla Institute for Immunology have made breakthroughs finding evidence that ALS could be an ...
Medicare beneficiaries with amyotrophic lateral sclerosis (ALS) were found to have more than 3 times the Medicare expenditures and beneficiary liability of the average Medicare beneficiary.
The ALS Network’s 23rd annual Inland Empire Walk and Roll to Cure ALS, formerly the Walk to Defeat ALS, will be held Oct. 19 at Miller Park Amphitheater, 17002 Arrow Blvd., Fontana. The Walk and Roll ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback